This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information
Home

Menu

Close

RTIs & Acute Otitis MediaUpper Respiratory Tract Infections (Upper RTIs)Acute Bacterial SinusitisPharyngitis/TonsillitisAcute Otitis MediaAcute Otitis MediaLower Respiratory Tract Infections (Lower RTIs)Community-Acquired PneumoniaAcute Bacterial Exacerbation of Chronic BronchitisSTIsSexually Transmitted Infections (STIs)Infections by Chlamydia trachomatisInfections by Neisseria gonorrhoeaeChancroid/Genital Ulcers MenSSTIsSkin and Soft-Tissue Infections (SSTIs)Uncomplicated Skin and Soft-Tissue InfectionsSafetySafetySafetyAdditional InformationAdditional InformationIndication and SusceptibilityFormulationsMode of ActionReconstitution of Powder for Oral Suspension for PediatricsPediatric AdministrationResourcesResourcesPrescribing InformationEventsMaterialsVideos

Sexually Transmitted Infections  |  Chancroid/Genital Ulcers Men

Chancroid/Genital Ulcers Men

Administration

Guidelines

Epidemiology

Efficacy

Tab Number 5

Administration

Adults1

Single 1000 mg dose

  • ZITHROMAX should be given as a single daily dose1
  • ZITHROMAX tablets and suspension can be taken with or without food1
Renal Impairment1

No dose adjustment is necessary in patients with mild to moderate renal impairment (glomerular filtration rate [GFR] of 10–80 mL/min). Caution should be exercised when ZITHROMAX is administered to patients with severe renal impairment (GFR <10 mL/min)

Hepatic Impairment1

The same dosage as in patients with normal hepatic function may be used in patients with mild to moderate hepatic impairment

GuidelinesAzithromycin: recommended in infection control guidelinesAzithromycin is recommended as a treatment option in the following guidelines: Management of Chancroid2

European Guidelines 2017

 View guidelines Loading Sexually Transmitted Diseases Treatment Guidelines3

Centers for Disease Control and Prevention (CDC) 2021

 View guidelines Loading
Epidemiology

Chancroid prevalence has declined in the United States. When infection occurs, it is commonly associated with sporadic outbreaks3

Worldwide, chancroid appears to have decreased as well, although infection might still occur in certain Africa regions and the Caribbean3

EfficacyZITHROMAX – As effective as ceftriaxone intramuscular (IM) injection when treating chancroid4Comparison of Azithromycin and Ceftriaxone for the Treatment of Chancroid

1st Follow-Up Visit: Oral vs IM

Complete healing of lesions (%)

Adapted from Martin et al. 19954
*not statistically significant

3rd Follow-Up Visit: Oral vs IM

Complete healing of lesions (%)

Adapted from Martin et al. 19954
*not statistically significant

Martin et al. 19954
  • A randomized, unblinded, multicenter, prospective study to determine the efficacy of single-dose azithromycin for the treatment of chancroid
  • At last follow-up visit, all 32 patients whose cultures were positive for Haemophilus ducreyi and treated with azithromycin were clinically cured, and in all 33 culture-positive ceftriaxone-treated cases, there was either clinical improvement or cure
  • A single 1 g oral dose of azithromycin is as effective as a 250 mg IM dose of ceftriaxone for the treatment of chancroid
BadgeKickerHeader of this CTA card goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…

Button Loading

Hyperlink

Hyperlink

Hyperlink

Optional footnote area for disclaimers etc.

TitleZITHROMAX is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients.1
The most recent local resistance data available must always take precedence when selecting antimicrobial therapy; in settings where local resistance data are not available, national and international guidelines can help inform antimicrobial choice.
As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms including fungi is recommended. Clostridium difficile associated diarrhea has been reported with azithromycin, and may range in severity from mild diarrhea to fatal colitis.1
The prevalence of acquired resistance to azithromycin may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. Expert advice should be sought when the local prevalence of resistance is such that the utility of azithromycin in at least some types of infections is questionable.1
In patients with severe renal impairment (GFR <10 mL/min), a 33% increase in systemic exposure to ZITHROMAX was observed.1You might also be interested in...Sexually Transmitted Infections Infections by Chlamydia trachomatis Find out more LoadingSexually Transmitted Infections Infections by Neisseria gonorrhoeae Find out more LoadingResources ZITHROMAX® Mode of Action Find out more Loading

References:

Pfizer Malaysia ZITHROMAX Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17705. Accessed January 2024.Lautenschlager S, et al. Int J STD AIDS. 2017;28(4):324–9.Workowski KA, et al. MMWR Recomm Rep. 2021;70(4):1–192.Martin DH, et al. Clin Infect Dis. 1995;21:409–14.Sexually Transmitted Infections ZITHROMAX® Safety Information Find out more Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

PP-ZIT-MYS-0243-28FEB2024
You are now leaving the PfizerPro Malaysia website
​
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023